Amanda de Fraga Dias
Overview
Explore the profile of Amanda de Fraga Dias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Silva A, Scholl J, de Fraga Dias A, Weber A, Morrone F, Cruz-Lopez O, et al.
Purinergic Signal
. 2023 Oct;
PMID: 37906424
Bladder cancer (BC) is the most common cancer of the urinary tract. Bozepinib (BZP), a purine-derived molecule, is a potential compound for the treatment of cancer. Purinergic signaling consists of...
2.
Brum da Silva Nunes V, Dias C, Scholl J, SantAna A, de Fraga Dias A, Farias M, et al.
Discov Oncol
. 2022 Dec;
13(1):143.
PMID: 36581667
Purpose: Although risk-stratified chemotherapy regimens improve B-cell acute lymphoblastic leukemia (B-ALL) clinical outcome, relapse occurs in a significant number of cases. The identification of new therapeutic targets as well as...
3.
Vargas P, Scheffel T, Diz F, Rockenbach L, Grave N, Cappellari A, et al.
Purinergic Signal
. 2022 Aug;
18(4):481-494.
PMID: 35939198
Glioblastoma (GBM) is the most aggressive and lethal among the primary brain tumors, with a low survival rate and resistance to radio and chemotherapy. The P2Y is an adenosine diphosphate...
4.
Bruinsmann F, de Cristo Soares Alves A, de Fraga Dias A, Lopes Silva L, Visioli F, Pohlmann A, et al.
Int J Pharm
. 2022 Feb;
616:121563.
PMID: 35151819
Glioblastoma is the most common and lethal malignant brain tumor. Despite simvastatin (SVT) showing potential anticancer properties, its antitumoral effect against glioblastoma appears limited when the conventional oral administration route...
5.
de Fraga Dias A, Dallemole D, Bruinsmann F, Lopes Silva L, Cruz-Lopez O, Conejo-Garcia A, et al.
Nanomedicine (Lond)
. 2021 Sep;
16(23):2095-2115.
PMID: 34523353
To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC) as a potential treatment for glioblastoma (GBM). Characterization of nanocapsules was performed by diameter, polydispersity index, Zeta potential, pH and encapsulation efficiency....
6.
de Cristo Soares Alves A, Lavayen V, de Fraga Dias A, Bruinsmann F, Scholl J, Ce R, et al.
Nanomedicine (Lond)
. 2021 Jul;
16(20):1775-1790.
PMID: 34313137
To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III....
7.
de Fraga Dias A, Scholl J, Moritz C, Kagami L, das Neves G, Eifler-Lima V, et al.
Eur J Pharm Sci
. 2021 Mar;
162:105823.
PMID: 33781855
Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults and the current treatments only have a modest effect on patient survival. Recent studies show that bozepinib (BZP),...
8.
Lopes D, de Fraga Dias A, Lopes Silva L, Scholl J, Sevigny J, Battastini A, et al.
Purinergic Signal
. 2021 Mar;
17(2):273-284.
PMID: 33745072
Glioblastoma (GBM) is the most malignant and deadly brain tumor. GBM cells overexpress the CD73 enzyme, which controls the level of extracellular adenosine, an immunosuppressive molecule. Studies have shown that...
9.
Federico L, Silva G, de Fraga Dias A, Figueiro F, Battastini A, Santos C, et al.
Int J Biol Macromol
. 2021 Mar;
165(Pt B):3040-3050.
PMID: 33736292
Among several strategies related to cancer therapy targeting the modulation of αβ-tubulin has shown encouraging findings, more specifically when this is achieved by inhibitors located at the colchicine binding site....
10.
Moritz C, Boeno F, Vieira A, Munhoz S, Scholl J, de Fraga Dias A, et al.
Exp Physiol
. 2021 Feb;
106(4):1024-1037.
PMID: 33624912
New Finding: What is the central question of this study? How does moderate-intensity aerobic exercise affect the behaviour of purinergic enzymes in sedentary, overweight and physically active subjects? What is...